Schizophrenia is one of the top 15 leading causes of disability worldwide and is associated with significant health, social, and economic burdens. Varied clinical presentation and clinician knowledge deficits often contribute to a timely and accurate diagnosis. The Department of Veterans Affairs / Department of Defense (VA/DoD) Evidence-Based Practice Work Group convened a joint VA/DoD guideline development effort that included a multidisciplinary panel of practicing clinician experts and conformed to the Institute of Medicine's tenets for trustworthy clinical practice guidelines (CPGs). The guideline panel developed key questions in collaboration with the ECRI Institute, which systematically searched and evaluated the literature from 1 November 2011 to 31 November 2021 and developed and rated recommendations by using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) system. This guideline supported by the John Scott Hannon Veterans Health Care Improvement Act, intended to promote evidence-based management of schizophrenia and thereby improve patient’s clinical outcomes. The CPG is designed to assist primary care and mental health clinicians and specialists in the diagnosis of schizophrenia, determination of appropriate treatment, and delivery of individualized interventions with focus on mental health recovery. Reducing mental health morbidity is important for the health and well-being of active duty service members, Veterans, and their families. This poster presentation summarizes key features of the CPGs: the appropriate diagnosis of schizophrenia, target treatment goals, and nonpharmacologic and pharmacologic treatment.